Comparison · NCT01552681-sae
Baminercept 100 mg vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Baminercept 100 mg vs Placebo: serious adverse events. Trial comparisons, record NCT01552681-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01552681-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.152 | 0.0665 | 0.309 | wilson | |
| Risk in group 2 | 0.0526 | 0.00935 | 0.246 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0989 | -0.113 | 0.262 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.88 | 0.363 | 22.8 | log | |
| Odds ratio, group 1 over group 2 | 3.21 | 0.347 | 29.8 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Baminercept 100 mg than on Placebo | 10.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Baminercept 100 mg | Participants were randomized to receive one subcutaneous injection of 100 mg baminercept every week for 24 weeks. | 5 | 33 | EG000 |
| Group 2 | Placebo | Participants were randomized to receive one subcutaneous injection of placebo every week for 24 weeks. | 1 | 19 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From the time of administration of the first dose of study drug until the participant completed study participation, an average of 48 weeks.
Source ClinicalTrials.gov
Trial
- Title
- Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome
- NCT number
- NCT01552681
- Phases
- PHASE2
- Conditions
- Primary Sjögren's Syndrome
- Interventions
- Baminercept, Placebo
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Results first posted
- 2016-03-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01552681?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01552681-sae